

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Friday, October 06, 2017 2:25 PM  
**To:** 'Rizwana Sproule'  
**Cc:** 'Alex Babayan'; 'Nadia Agopyan'  
**Subject:** Clinical Safety Information Request 10.6.17

**Importance:** High

Dear Dr. Sproule,

Can you please provide subjects IDs for the following:

1. All subjects who received at least one dose of tocilizumab
2. Subjects with the following AEs:
  - a. Cardiac arrest
  - b. Cardiac failure (to include the group terms: Acute left ventricular failure, left ventricular failure, cardiac failure, ejection fraction decreased)
  - c. Renal insufficiency (to include: Acute kidney injury, blood creatinine increased)
  - d. Pulmonary edema (to include: pulmonary congestion, pulmonary edema, re-expansion pulmonary edema)
  - e. Rash (to include erythema, papule, rash, rash erythematous, rash maculo-papular).
  - f. Capillary leak syndrome
  - g. Thrombosis: (to include: Deep vein thrombosis, Embolism, Embolism venous, Pulmonary embolism, Splenic infarction, Splenic vein thrombosis, Subclavianvein thrombosis, Thrombosis in device

**Response by COB today if all possible!**

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."